<DOC>
	<DOC>NCT00370669</DOC>
	<brief_summary>to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)</brief_summary>
	<brief_title>Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema</brief_title>
	<detailed_description>we entered 150 eyes into the study that recruitment of cases finished recently.Eligible eyes randomly assign to one of the study arms including intravitreal bevacizumzb, intravitreal bevacizumzb/triamcinolone and macular photocoagulation groups. Every patient needs at least 1 year followup. During this time BCVA, OCT, FA will be done for each patient and inaccording to interpretation of datas and fundus exam repeatation of injection will be done.</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>case with clear media IOP below 23 mm/Hg female after menopause at least for 12 months or had 2 contraceptive roots visual acuity between 20/50 to 20/320 no PRP or N.d YAG laser in past 6 months no intraocular surgery in past 12 months CVA in past 12 months blood sugar above 250 active infection in extraocular adnexa</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>CSME</keyword>
	<keyword>MPC</keyword>
	<keyword>Triamcinolone acetonide</keyword>
</DOC>